Nutriband Inc. (NTRB)
|Net Income (ttm)||-2.93M|
|Trading Day||April 16|
|Day's Range||20.99 - 21.00|
|52-Week Range||3.00 - 32.00|
There are no news available yet.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. Its product line consists of an energy patch line; a weight management patch line; a multivitamin patch line; a children's multivitamin patch line; an amino acid patch line; an anti-wrinkle patch line; an insect repellant patch line; a detox patch line; a PMS... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2020, Nutriband's revenue was $943,702, an increase of 154.61% compared to the previous year's $370,647. Losses were -$2.93 million, 7.76% more than in 2019.
The average 12-month stock price forecast for Nutriband is 24.00, which is an increase of 14.34% from the latest price.